Journal
CANCERS
Volume 14, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/cancers14010140
Keywords
hepatocellular carcinoma; tumor-associated antigens; cancer immunotherapy
Categories
Funding
- FP-7 HEPAVAC [602893]
- Transcan2HEPAMUT project [643638]
- Italian Ministry of Health through Institutional Ricerca Corrente
- POR FESR 2014/2020 Campania OncoTerapie
- Ricerca Corrente
- POR FESR 2014/2020 NanoCAN
Ask authors/readers for more resources
This study aimed to identify HCC-specific overexpressed proteins and potential epitopes recognized by CD8(+) cytotoxic T cells that may share homology to viral epitopes. The results showed that circulating CD8(+) T cells targeted both HCC and viral-related epitopes, suggesting their potential use in HCC-specific immunotherapies.
Simple Summary HCC is a disease with highly unmet medical needs. Specific target antigens for the development of active (vaccine) and/or passive (adoptive T-cell therapy) cancer immunotherapy strategies are needed. The aim of our study was to exploit the high number of data derived from a public dataset to identify HCC-specific overexpressed proteins, leading to potential epitopes recognized by CD8(+) cytotoxic T cells, which may share homology to viral epitopes. Circulating CD8(+) T cells were revealed to be targeting both HCC and viral-related epitopes, suggesting the possible use in HCC-specific immunotherapies. Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, only a few treatments are available, most of which are effective only for the early stages of the disease. Therefore, there is an urgent needing for potential markers for a specifically targeted therapy. Candidate proteins were selected from datasets of The Human Protein Atlas, in order to identify specific tumor-associated proteins overexpressed in HCC samples associated with poor prognosis. Potential epitopes were predicted from such proteins, and homology with peptides derived from viral proteins was assessed. A multiparametric validation was performed, including recognition by PBMCs from HCC-patients and healthy donors, showing a T-cell cross-reactivity with paired epitopes. These results provide novel HCC-specific tumor-associated antigens (TAAs) for immunotherapeutic anti-HCC strategies potentially able to expand pre-existing virus-specific CD8(+) T cells with superior anticancer efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available